{"transactions":[{"id":685273,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T20:05:03.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":false,"shares":24369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable as of the date hereof."}],"balance_after":11608,"derivative":{"exercise_price":6.36,"expiration_date":"2029-04-27","underlying":"Series A Common Stock","underlying_shares":24369},"source":{"system":"sec-edgar","filing":"0001193125-26-354018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526354018/ownership.xml","form_type":"4"}},{"id":685272,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T20:05:03.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":false,"shares":326618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable as of the date hereof."}],"balance_after":31455,"derivative":{"exercise_price":6.36,"expiration_date":"2029-04-27","underlying":"Series A Common Stock","underlying_shares":326618},"source":{"system":"sec-edgar","filing":"0001193125-26-354018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526354018/ownership.xml","form_type":"4"}},{"id":685271,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2026-08-17T20:05:03.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":350987,"price":10.2328,"value":3591579.7736,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":62161,"source":{"system":"sec-edgar","filing":"0001193125-26-354018","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526354018/ownership.xml","form_type":"4"}},{"id":685270,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2026-08-17T20:05:03.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":true,"shares":24369,"price":6.36,"value":154986.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."}],"balance_after":413148,"source":{"system":"sec-edgar","filing":"0001193125-26-354018","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526354018/ownership.xml","form_type":"4"}},{"id":685269,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2026-08-17T20:05:03.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":true,"shares":326618,"price":6.36,"value":2077290.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."}],"balance_after":388779,"source":{"system":"sec-edgar","filing":"0001193125-26-354018","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526354018/ownership.xml","form_type":"4"}},{"id":689025,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T23:41:11.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":false,"shares":10455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable as of the date hereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This option is fully vested and exercisable as of the date hereof."}],"balance_after":35977,"derivative":{"exercise_price":6.36,"underlying":"Series A Common Stock","underlying_shares":10455},"source":{"system":"sec-edgar","filing":"0001193125-26-347407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526347407/ownership.xml","form_type":"4"}},{"id":689024,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T23:41:11.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":false,"shares":9751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable as of the date hereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This option is fully vested and exercisable as of the date hereof."}],"balance_after":358073,"derivative":{"exercise_price":6.36,"underlying":"Series A Common Stock","underlying_shares":9751},"source":{"system":"sec-edgar","filing":"0001193125-26-347407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526347407/ownership.xml","form_type":"4"}},{"id":689023,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2026-08-12T23:41:11.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":20206,"price":9.9548,"value":201146.6888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":62161,"source":{"system":"sec-edgar","filing":"0001193125-26-347407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526347407/ownership.xml","form_type":"4"}},{"id":689022,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2026-08-12T23:41:11.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":true,"shares":10455,"price":6.36,"value":66493.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."}],"balance_after":82367,"source":{"system":"sec-edgar","filing":"0001193125-26-347407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526347407/ownership.xml","form_type":"4"}},{"id":689021,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2026-08-12T23:41:11.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":true,"shares":9751,"price":6.36,"value":62016.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."}],"balance_after":71912,"source":{"system":"sec-edgar","filing":"0001193125-26-347407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526347407/ownership.xml","form_type":"4"}},{"id":704706,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2026-07-22T20:05:22.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":64051,"price":7.7605,"value":497067.7855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":741570,"source":{"system":"sec-edgar","filing":"0001193125-26-312397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000119312526312397/ownership.xml","form_type":"4"}},{"id":704612,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin. Officer"}}],"security":"Series A Common Stock","published_at":"2026-07-22T20:05:16.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":10545,"price":7.7603,"value":81832.3635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":224414,"source":{"system":"sec-edgar","filing":"0001193125-26-312394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526312394/ownership.xml","form_type":"4"}},{"id":704611,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Stock","published_at":"2026-07-22T20:05:03.000Z","date":"2026-07-20","kind":"sale","planned":true,"acquired":false,"shares":18844,"price":7.4575,"value":140529.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.17 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":62161,"source":{"system":"sec-edgar","filing":"0001193125-26-312386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526312386/ownership.xml","form_type":"4"}},{"id":737603,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:23:34.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074055","document":"tm2617570-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465926074055/tm2617570-6_4seq1.xml","form_type":"4"}},{"id":737766,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":38167,"kind":"person","name":"Hoelscher Paul W.","position":1,"cik":"0001611468","reported_name":"Hoelscher Paul W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:22:23.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074052","document":"tm2617570-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611468/000110465926074052/tm2617570-5_4seq1.xml","form_type":"4"}},{"id":737803,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":36383,"kind":"person","name":"Jarrett Jennifer","position":1,"cik":"0001671311","reported_name":"Jarrett Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:21:43.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074050","document":"tm2617570-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671311/000110465926074050/tm2617570-4_4seq1.xml","form_type":"4"}},{"id":737585,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":38095,"kind":"person","name":"GRAMMER ELIZABETH A","position":1,"cik":"0001213041","reported_name":"GRAMMER ELIZABETH A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:20:55.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074047","document":"tm2617570-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213041/000110465926074047/tm2617570-3_4seq1.xml","form_type":"4"}},{"id":737526,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:20:22.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074045","document":"tm2617570-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926074045/tm2617570-2_4seq1.xml","form_type":"4"}},{"id":737767,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:19:52.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074044","document":"tm2617570-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465926074044/tm2617570-1_4seq1.xml","form_type":"4"}},{"id":757277,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T01:16:36.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":7.27,"expiration_date":"2036-05-27","underlying":"Series A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-069124","document":"tm2616578-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926069124/tm2616578-4_4seq1.xml","form_type":"4"}},{"id":756785,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42746,"kind":"person","name":"Grauer Andreas","position":1,"cik":"0001770511","reported_name":"Grauer Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T01:15:27.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":7.27,"expiration_date":"2036-05-27","underlying":"Series A Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-26-069123","document":"tm2616578-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926069123/tm2616578-3_4seq1.xml","form_type":"4"}},{"id":756784,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin. Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T01:14:55.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":7.27,"expiration_date":"2036-05-27","underlying":"Series A Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-26-069122","document":"tm2616578-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926069122/tm2616578-2_4seq1.xml","form_type":"4"}},{"id":757039,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T01:13:45.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":7.27,"expiration_date":"2036-05-27","underlying":"Series A Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-26-069121","document":"tm2616578-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926069121/tm2616578-1_4seq1.xml","form_type":"4"}},{"id":778741,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42746,"kind":"person","name":"Grauer Andreas","position":1,"cik":"0001770511","reported_name":"Grauer Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-14T21:15:39.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":264759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on April 20, 2027, with the remaining 75% vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":264759,"derivative":{"exercise_price":6.44,"expiration_date":"2036-04-19","underlying":"Series A Common Stock","underlying_shares":264759},"source":{"system":"sec-edgar","filing":"0001104659-26-061327","document":"tm2614553-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926061327/tm2614553-2_4seq1.xml","form_type":"4"}},{"id":890323,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin. Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-20T21:43:57.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":88000,"derivative":{"exercise_price":5.38,"expiration_date":"2036-02-18","underlying":"Series A Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001104659-26-018196","document":"tm266959-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926018196/tm266959-4_4seq1.xml","form_type":"4"}},{"id":890322,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin. Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-20T21:43:57.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":234959,"source":{"system":"sec-edgar","filing":"0001104659-26-018196","document":"tm266959-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926018196/tm266959-4_4seq1.xml","form_type":"4"}},{"id":890656,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-20T21:41:03.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":256000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":256000,"derivative":{"exercise_price":5.38,"expiration_date":"2036-02-18","underlying":"Series A Common Stock","underlying_shares":256000},"source":{"system":"sec-edgar","filing":"0001104659-26-018193","document":"tm266959-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926018193/tm266959-2_4seq1.xml","form_type":"4"}},{"id":890655,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2026-02-20T21:41:03.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":128000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":805621,"source":{"system":"sec-edgar","filing":"0001104659-26-018193","document":"tm266959-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926018193/tm266959-2_4seq1.xml","form_type":"4"}},{"id":890933,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-20T21:39:20.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":88000,"derivative":{"exercise_price":5.38,"expiration_date":"2036-02-18","underlying":"Series A Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001104659-26-018191","document":"tm266959-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926018191/tm266959-1_4seq1.xml","form_type":"4"}},{"id":890932,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-20T21:39:20.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":59688,"source":{"system":"sec-edgar","filing":"0001104659-26-018191","document":"tm266959-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926018191/tm266959-1_4seq1.xml","form_type":"4"}},{"id":890691,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-20T16:42:48.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":88000,"derivative":{"exercise_price":5.38,"expiration_date":"2036-02-18","underlying":"Series A Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001104659-26-018194","document":"tm266959-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465926018194/tm266959-3_4seq1.xml","form_type":"4"}},{"id":890690,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-20T16:42:48.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":147296,"source":{"system":"sec-edgar","filing":"0001104659-26-018194","document":"tm266959-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465926018194/tm266959-3_4seq1.xml","form_type":"4"}},{"id":907549,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2026-02-12T21:08:51.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":12101,"price":5.3603,"value":64864.9903,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":677621,"source":{"system":"sec-edgar","filing":"0001104659-26-014283","document":"tm266207-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926014283/tm266207-4_4seq1.xml","form_type":"4"}},{"id":907755,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-12T21:07:20.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":1312,"price":5.3603,"value":7032.7136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":15688,"source":{"system":"sec-edgar","filing":"0001104659-26-014277","document":"tm266207-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465926014277/tm266207-3_4seq1.xml","form_type":"4"}},{"id":907243,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin. Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-12T21:05:13.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":2622,"price":5.3602,"value":14054.4444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":190959,"source":{"system":"sec-edgar","filing":"0001104659-26-014266","document":"tm266207-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926014266/tm266207-1_4seq1.xml","form_type":"4"}},{"id":907569,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Common Stock","published_at":"2026-02-12T16:06:10.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":3640,"price":5.3602,"value":19511.128,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":103296,"source":{"system":"sec-edgar","filing":"0001104659-26-014272","document":"tm266207-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465926014272/tm266207-2_4seq1.xml","form_type":"4"}},{"id":991098,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Common Stock","published_at":"2025-11-21T23:13:11.000Z","date":"2025-11-20","kind":"sale","planned":true,"acquired":false,"shares":37688,"price":7.6942,"value":289979.0096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":81005,"source":{"system":"sec-edgar","filing":"0001104659-25-115071","document":"tm2531988-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925115071/tm2531988-1_4seq1.xml","form_type":"4"}},{"id":1005635,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin. Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-06T21:43:41.000Z","date":"2025-11-04","kind":"grant","planned":false,"acquired":true,"shares":13367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted in connection with the Reporting Person's promotion within the Company. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":13367,"derivative":{"exercise_price":7.61,"expiration_date":"2035-11-03","underlying":"Series A Common Stock","underlying_shares":13367},"source":{"system":"sec-edgar","filing":"0001104659-25-107806","document":"tm2530509-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925107806/tm2530509-1_4seq1.xml","form_type":"4"}},{"id":1005634,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin. Officer"}}],"security":"Series A Common Stock","published_at":"2025-11-06T21:43:41.000Z","date":"2025-11-04","kind":"grant","planned":false,"acquired":true,"shares":9855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted in connection with the Reporting Person's promotion within the Company. Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":193581,"source":{"system":"sec-edgar","filing":"0001104659-25-107806","document":"tm2530509-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925107806/tm2530509-1_4seq1.xml","form_type":"4"}},{"id":1082784,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2025-07-23T20:16:25.000Z","date":"2025-07-21","kind":"sale","planned":false,"acquired":false,"shares":65478,"price":9.1346,"value":598115.3388,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":689722,"source":{"system":"sec-edgar","filing":"0001104659-25-070017","document":"tm2521574-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465925070017/tm2521574-3_4seq1.xml","form_type":"4"}},{"id":1082710,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Series A Common Stock","published_at":"2025-07-23T20:14:11.000Z","date":"2025-07-21","kind":"sale","planned":false,"acquired":false,"shares":10780,"price":9.1346,"value":98470.988,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":183726,"source":{"system":"sec-edgar","filing":"0001104659-25-070013","document":"tm2521574-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925070013/tm2521574-1_4seq1.xml","form_type":"4"}},{"id":1082795,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Common Stock","published_at":"2025-07-23T16:15:22.000Z","date":"2025-07-21","kind":"sale","planned":false,"acquired":false,"shares":8277,"price":9.1346,"value":75607.0842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":106936,"source":{"system":"sec-edgar","filing":"0001104659-25-070015","document":"tm2521574-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465925070015/tm2521574-2_4seq1.xml","form_type":"4"}},{"id":1116069,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":25937,"kind":"person","name":"Walbert Timothy P","position":1,"cik":"0001349376","reported_name":"Walbert Timothy P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:43:22.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":32250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32250,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":32250},"source":{"system":"sec-edgar","filing":"0001104659-25-058226","document":"tm2517621-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1349376/000110465925058226/tm2517621-7_4seq1.xml","form_type":"4"}},{"id":1116145,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:42:20.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":32250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32250,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":32250},"source":{"system":"sec-edgar","filing":"0001104659-25-058225","document":"tm2517621-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465925058225/tm2517621-6_4seq1.xml","form_type":"4"}},{"id":1116144,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:42:20.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":28522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":28522,"derivative":{"exercise_price":5.56,"expiration_date":"2035-06-05","underlying":"Series A Common Stock","underlying_shares":28522},"source":{"system":"sec-edgar","filing":"0001104659-25-058225","document":"tm2517621-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465925058225/tm2517621-6_4seq1.xml","form_type":"4"}},{"id":1116285,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:41:17.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":27268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":27268,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":27268},"source":{"system":"sec-edgar","filing":"0001104659-25-058224","document":"tm2517621-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465925058224/tm2517621-5_4seq1.xml","form_type":"4"}},{"id":1116042,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:40:13.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":32250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32250,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":32250},"source":{"system":"sec-edgar","filing":"0001104659-25-058223","document":"tm2517621-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925058223/tm2517621-4_4seq1.xml","form_type":"4"}},{"id":1116340,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":36383,"kind":"person","name":"Jarrett Jennifer","position":1,"cik":"0001671311","reported_name":"Jarrett Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:38:50.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":27268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":27268,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":27268},"source":{"system":"sec-edgar","filing":"0001104659-25-058222","document":"tm2517621-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671311/000110465925058222/tm2517621-3_4seq1.xml","form_type":"4"}},{"id":1116282,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":38167,"kind":"person","name":"Hoelscher Paul W.","position":1,"cik":"0001611468","reported_name":"Hoelscher Paul W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:37:31.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":32250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32250,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":32250},"source":{"system":"sec-edgar","filing":"0001104659-25-058221","document":"tm2517621-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611468/000110465925058221/tm2517621-2_4seq1.xml","form_type":"4"}},{"id":1116132,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":38095,"kind":"person","name":"GRAMMER ELIZABETH A","position":1,"cik":"0001213041","reported_name":"GRAMMER ELIZABETH A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:36:18.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":32250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32250,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":32250},"source":{"system":"sec-edgar","filing":"0001104659-25-058220","document":"tm2517621-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213041/000110465925058220/tm2517621-1_4seq1.xml","form_type":"4"}},{"id":1278702,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-07T21:43:56.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":472000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":472000,"derivative":{"exercise_price":4.71,"expiration_date":"2035-02-05","underlying":"Series A Common Stock","underlying_shares":472000},"source":{"system":"sec-edgar","filing":"0001104659-25-010587","document":"tm255919-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465925010587/tm255919-3_4seq1.xml","form_type":"4"}},{"id":1278701,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2025-02-07T21:43:56.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":755200,"source":{"system":"sec-edgar","filing":"0001104659-25-010587","document":"tm255919-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465925010587/tm255919-3_4seq1.xml","form_type":"4"}},{"id":1278478,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-07T21:42:54.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":138000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":138000,"derivative":{"exercise_price":4.71,"expiration_date":"2035-02-05","underlying":"Series A Common Stock","underlying_shares":138000},"source":{"system":"sec-edgar","filing":"0001104659-25-010586","document":"tm255919-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925010586/tm255919-2_4seq1.xml","form_type":"4"}},{"id":1278477,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Series A Common Stock","published_at":"2025-02-07T21:42:54.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":194506,"source":{"system":"sec-edgar","filing":"0001104659-25-010586","document":"tm255919-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925010586/tm255919-2_4seq1.xml","form_type":"4"}},{"id":1278904,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-07T21:41:47.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":69000,"derivative":{"exercise_price":4.71,"expiration_date":"2035-02-05","underlying":"Series A Common Stock","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0001104659-25-010584","document":"tm255919-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465925010584/tm255919-1_4seq1.xml","form_type":"4"}},{"id":1278903,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Common Stock","published_at":"2025-02-07T21:41:47.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0001104659-25-010584","document":"tm255919-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465925010584/tm255919-1_4seq1.xml","form_type":"4"}},{"id":1278763,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-07T16:44:52.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":138000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":138000,"derivative":{"exercise_price":4.71,"expiration_date":"2035-02-05","underlying":"Series A Common Stock","underlying_shares":138000},"source":{"system":"sec-edgar","filing":"0001104659-25-010589","document":"tm255919-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465925010589/tm255919-4_4seq1.xml","form_type":"4"}},{"id":1278762,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Common Stock","published_at":"2025-02-07T16:44:52.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":115213,"source":{"system":"sec-edgar","filing":"0001104659-25-010589","document":"tm255919-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465925010589/tm255919-4_4seq1.xml","form_type":"4"}},{"id":1440784,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":36383,"kind":"person","name":"Jarrett Jennifer","position":1,"cik":"0001671311","reported_name":"Jarrett Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T20:09:40.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":113895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following August 1, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":113895,"derivative":{"exercise_price":3.48,"expiration_date":"2034-07-31","underlying":"Series A Common Stock","underlying_shares":113895},"source":{"system":"sec-edgar","filing":"0001104659-24-085820","document":"tm2420761-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671311/000110465924085820/tm2420761-4_4seq1.xml","form_type":"4"}},{"id":1440729,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T20:08:24.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":113895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following August 1, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":113895,"derivative":{"exercise_price":3.48,"expiration_date":"2034-07-31","underlying":"Series A Common Stock","underlying_shares":113895},"source":{"system":"sec-edgar","filing":"0001104659-24-085818","document":"tm2420761-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465924085818/tm2420761-3_4seq1.xml","form_type":"4"}},{"id":1448603,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Common Stock","published_at":"2024-07-25T20:05:09.000Z","date":"2024-07-23","kind":"sale","planned":true,"acquired":false,"shares":23625,"price":3.1674,"value":74829.825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":118693,"source":{"system":"sec-edgar","filing":"0001104659-24-082630","document":"tm2420121-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924082630/tm2420121-1_4seq1.xml","form_type":"4"}},{"id":1449839,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Series A Common Stock","published_at":"2024-07-23T20:05:50.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":10914,"price":3.0997,"value":33830.1258,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":160506,"source":{"system":"sec-edgar","filing":"0001104659-24-081891","document":"tm2420000d2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924081891/tm2420000d2_4seq1.xml","form_type":"4"}},{"id":1449838,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Common Stock","published_at":"2024-07-23T20:05:09.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":14062,"price":3.1009,"value":43604.8558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":142318,"source":{"system":"sec-edgar","filing":"0001104659-24-081887","document":"tm2420000-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924081887/tm2420000-1_4.xml","form_type":"4"}},{"id":1449933,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Common Stock","published_at":"2024-07-23T16:06:24.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":8357,"price":3.1004,"value":25910.0428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":81213,"source":{"system":"sec-edgar","filing":"0001104659-24-081892","document":"tm2420000-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465924081892/tm2420000-3_4seq1.xml","form_type":"4"}},{"id":1486322,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":25937,"kind":"person","name":"Walbert Timothy P","position":1,"cik":"0001349376","reported_name":"Walbert Timothy P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:08:05.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":9279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":9279,"derivative":{"exercise_price":4.64,"expiration_date":"2034-06-04","underlying":"Series A Common Stock","underlying_shares":9279},"source":{"system":"sec-edgar","filing":"0001104659-24-069639","document":"tm2416701-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1349376/000110465924069639/tm2416701-5_4seq1.xml","form_type":"4"}},{"id":1486407,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:07:35.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":51459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":51459,"derivative":{"exercise_price":4.64,"expiration_date":"2034-06-04","underlying":"Series A Common Stock","underlying_shares":51459},"source":{"system":"sec-edgar","filing":"0001104659-24-069637","document":"tm2416701-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465924069637/tm2416701-4_4seq1.xml","form_type":"4"}},{"id":1486281,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":15164,"kind":"person","name":"Parsey Merdad","position":1,"cik":"0001792150","reported_name":"Parsey Merdad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:07:02.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":51459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":51459,"derivative":{"exercise_price":4.64,"expiration_date":"2034-06-04","underlying":"Series A Common Stock","underlying_shares":51459},"source":{"system":"sec-edgar","filing":"0001104659-24-069636","document":"tm2416701-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924069636/tm2416701-3_4seq1.xml","form_type":"4"}},{"id":1486715,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":38167,"kind":"person","name":"Hoelscher Paul W.","position":1,"cik":"0001611468","reported_name":"Hoelscher Paul W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:05:44.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":9279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":9279,"derivative":{"exercise_price":4.64,"expiration_date":"2034-06-04","underlying":"Series A Common Stock","underlying_shares":9279},"source":{"system":"sec-edgar","filing":"0001104659-24-069632","document":"tm2416701-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611468/000110465924069632/tm2416701-2_4seq1.xml","form_type":"4"}},{"id":1486389,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":38095,"kind":"person","name":"GRAMMER ELIZABETH A","position":1,"cik":"0001213041","reported_name":"GRAMMER ELIZABETH A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:05:18.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":51459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":51459,"derivative":{"exercise_price":4.64,"expiration_date":"2034-06-04","underlying":"Series A Common Stock","underlying_shares":51459},"source":{"system":"sec-edgar","filing":"0001104659-24-069626","document":"tm2416701-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213041/000110465924069626/tm2416701-1_4seq1.xml","form_type":"4"}},{"id":1523501,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":42833,"kind":"person","name":"Chauche Thierry","position":1,"cik":"0001895174","reported_name":"Chauche Thierry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-08T20:06:44.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":587181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on May 6, 2025, with the remainder vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":587181,"derivative":{"exercise_price":4.28,"expiration_date":"2034-05-05","underlying":"Series A Common Stock","underlying_shares":587181},"source":{"system":"sec-edgar","filing":"0001104659-24-058661","document":"tm2413886-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895174/000110465924058661/tm2413886-2_4seq1.xml","form_type":"4"}},{"id":1548930,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":25937,"kind":"person","name":"Walbert Timothy P","position":1,"cik":"0001349376","reported_name":"Walbert Timothy P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:19:01.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":73014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following April 1, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":73014,"derivative":{"exercise_price":5.23,"expiration_date":"2034-03-31","underlying":"Series A Common Stock","underlying_shares":73014},"source":{"system":"sec-edgar","filing":"0001104659-24-043264","document":"tm2410971-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1349376/000110465924043264/tm2410971-4_4seq1.xml","form_type":"4"}},{"id":1549529,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":38167,"kind":"person","name":"Hoelscher Paul W.","position":1,"cik":"0001611468","reported_name":"Hoelscher Paul W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:17:03.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":73014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following April 1, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":73014,"derivative":{"exercise_price":5.23,"expiration_date":"2034-03-31","underlying":"Series A Common Stock","underlying_shares":73014},"source":{"system":"sec-edgar","filing":"0001104659-24-043263","document":"tm2410971-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611468/000110465924043263/tm2410971-3_4seq1.xml","form_type":"4"}},{"id":1558400,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2024-03-28T20:08:37.000Z","date":"2024-03-26","kind":"purchase","planned":false,"acquired":true,"shares":12100,"price":5.267,"value":63730.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.24 per share to $5.2999 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price."}],"balance_after":639200,"source":{"system":"sec-edgar","filing":"0001104659-24-040517","document":"tm2410115-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465924040517/tm2410115-1_4seq1.xml","form_type":"4"}},{"id":1664996,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T22:00:36.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":true,"shares":6997,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 7"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person, as Trustee of the Blue Mountain Trust, dated April 29, 2019 (the \"Blue Mountain Trust\") received 6,997 shares of Series A Common Stock of the Issuer in the distribution by NEA Partners 13 on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person is Trustee of the Blue Mountain Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Blue Mountain Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":6997,"source":{"system":"sec-edgar","filing":"0001209191-24-002501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000120919124002501/doc4.xml","form_type":"4"}},{"id":1664995,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T22:00:36.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"NEA Partners 13 made a pro rata distribution for no consideration of an aggregate of 260,950 shares of Series A Common Stock of the Issuer to its limited partners on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a director of NEA 13 LTD, the sole general partner of NEA Partners 13, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-002501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000120919124002501/doc4.xml","form_type":"4"}},{"id":1664994,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T22:00:36.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":true,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"NEA Partners 13 received 260,950 shares of Series A Common Stock of the Issuer in the distribution made by NEA 13 on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a director of NEA 13 LTD, the sole general partner of NEA Partners 13, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":260950,"source":{"system":"sec-edgar","filing":"0001209191-24-002501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000120919124002501/doc4.xml","form_type":"4"}},{"id":1664993,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T22:00:36.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 13, L.P. (\"NEA 13\") made a pro rata distribution of 850,000 shares of Series A Common Stock of the Issuer to its general partner and limited partners for no consideration on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a director of NEA 13 GP, LTD (\"NEA 13 LTD\"), which is the sole general partner of NEA Partners 13, L.P. (\"NEA Partners 13\"). NEA Partners 13 is the sole general partner of NEA 13, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":3000275,"source":{"system":"sec-edgar","filing":"0001209191-24-002501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000120919124002501/doc4.xml","form_type":"4"}},{"id":1664988,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81978,"kind":"person","name":"KERINS PATRICK J","position":1,"cik":"0001235112","reported_name":"KERINS PATRICK J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:59:07.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":true,"shares":13139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person received 13,139 shares of Series A Common Stock of the Issuer in the distribution by NEA Partners 13 on January 29, 2024."}],"balance_after":13139,"source":{"system":"sec-edgar","filing":"0001209191-24-002500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235112/000120919124002500/doc4.xml","form_type":"4"}},{"id":1664987,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81978,"kind":"person","name":"KERINS PATRICK J","position":1,"cik":"0001235112","reported_name":"KERINS PATRICK J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:59:07.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"NEA Partners 13 made a pro rata distribution for no consideration of an aggregate of 260,950 shares of Series A Common Stock of the Issuer to its limited partners on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a director of NEA 13 LTD, the sole general partner of NEA Partners 13, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-002500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235112/000120919124002500/doc4.xml","form_type":"4"}},{"id":1664986,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81978,"kind":"person","name":"KERINS PATRICK J","position":1,"cik":"0001235112","reported_name":"KERINS PATRICK J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:59:07.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":true,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"NEA Partners 13 received 260,950 shares of Series A Common Stock of the Issuer in the distribution made by NEA 13 on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a director of NEA 13 LTD, the sole general partner of NEA Partners 13, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":260950,"source":{"system":"sec-edgar","filing":"0001209191-24-002500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235112/000120919124002500/doc4.xml","form_type":"4"}},{"id":1664985,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81978,"kind":"person","name":"KERINS PATRICK J","position":1,"cik":"0001235112","reported_name":"KERINS PATRICK J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:59:07.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 13, L.P. (\"NEA 13\") made a pro rata distribution of 850,000 shares of Series A Common Stock of the Issuer to its general partner and limited partners for no consideration on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a director of NEA 13 GP, LTD (\"NEA 13 LTD\"), which is the sole general partner of NEA Partners 13, L.P. (\"NEA Partners 13\"). NEA Partners 13 is the sole general partner of NEA 13, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":3000275,"source":{"system":"sec-edgar","filing":"0001209191-24-002500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235112/000120919124002500/doc4.xml","form_type":"4"}},{"id":1664975,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:57:44.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":true,"shares":11300,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 7"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person, as Trustee of the Baskett-McKay Family Trust dated March 12, 2014 (the \"Baskett-McKay Family Trust\"), received 11,300 shares of Series A Common Stock of the Issuer in the distribution by NEA Partners 13 on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are held directly by the Baskett-McKay Family Trust. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Baskett-McKay Family Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":11300,"source":{"system":"sec-edgar","filing":"0001209191-24-002499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000120919124002499/doc4.xml","form_type":"4"}},{"id":1664974,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:57:44.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"NEA Partners 13 made a pro rata distribution for no consideration of an aggregate of 260,950 shares of Series A Common Stock of the Issuer to its limited partners on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a director of NEA 13 LTD, the sole general partner of NEA Partners 13, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-002499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000120919124002499/doc4.xml","form_type":"4"}},{"id":1664973,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:57:44.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":true,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"NEA Partners 13 received 260,950 shares of Series A Common Stock of the Issuer in the distribution made by NEA 13 on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a director of NEA 13 LTD, the sole general partner of NEA Partners 13, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":260950,"source":{"system":"sec-edgar","filing":"0001209191-24-002499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000120919124002499/doc4.xml","form_type":"4"}},{"id":1664972,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:57:44.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 13, L.P. (\"NEA 13\") made a pro rata distribution of 850,000 shares of Series A Common Stock of the Issuer to its general partner and limited partners for no consideration on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a director of NEA 13 GP, LTD (\"NEA 13 LTD\"), which is the sole general partner of NEA Partners 13, L.P. (\"NEA Partners 13\"). NEA Partners 13 is the sole general partner of NEA 13, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Reporting Person has no pecuniary interest."}],"balance_after":3000275,"source":{"system":"sec-edgar","filing":"0001209191-24-002499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000120919124002499/doc4.xml","form_type":"4"}},{"id":1665107,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81976,"kind":"organization","name":"NEA Partners 13, Limited Partnership","position":1,"cik":"0001460752","reported_name":"NEA Partners 13, Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81977,"kind":"organization","name":"NEA 13 GP, Ltd","position":2,"cik":"0001460751","reported_name":"NEA 13 GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:56:46.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"NEA Partners 13 made a pro rata distribution for no consideration of an aggregate of 260,950 shares of Series A Common Stock of the Issuer to its limited partners on January 29, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by NEA Partners 13 and indirectly held by NEA 13 LTD, the sole general partner of NEA Partners 13, and the Directors (NEA 13 LTD and the Directors together, the \"NEA Partners 13 Indirect Reporting Persons\"). The NEA Partners 13 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the NEA Partners 13 Indirect Reporting Persons have no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-002498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1460751/000120919124002498/doc4.xml","form_type":"4"}},{"id":1665106,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81976,"kind":"organization","name":"NEA Partners 13, Limited Partnership","position":1,"cik":"0001460752","reported_name":"NEA Partners 13, Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81977,"kind":"organization","name":"NEA 13 GP, Ltd","position":2,"cik":"0001460751","reported_name":"NEA 13 GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:56:46.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":true,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"NEA Partners 13 received 260,950 shares of Series A Common Stock of the Issuer in the distribution made by NEA 13 on January 29, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by NEA Partners 13 and indirectly held by NEA 13 LTD, the sole general partner of NEA Partners 13, and the Directors (NEA 13 LTD and the Directors together, the \"NEA Partners 13 Indirect Reporting Persons\"). The NEA Partners 13 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 13 in which the NEA Partners 13 Indirect Reporting Persons have no pecuniary interest."}],"balance_after":260950,"source":{"system":"sec-edgar","filing":"0001209191-24-002498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1460751/000120919124002498/doc4.xml","form_type":"4"}},{"id":1665105,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81976,"kind":"organization","name":"NEA Partners 13, Limited Partnership","position":1,"cik":"0001460752","reported_name":"NEA Partners 13, Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81977,"kind":"organization","name":"NEA 13 GP, Ltd","position":2,"cik":"0001460751","reported_name":"NEA 13 GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:56:46.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 13, L.P. (\"NEA 13\") made a pro rata distribution of 850,000 shares of Series A Common Stock of the Issuer to its general partner and limited partners for no consideration on January 29, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by NEA 13 and are indirectly held by NEA Partners 13, L.P. (\"NEA Partners 13\"), the sole general partner of NEA 13, NEA 13 GP, LTD (\"NEA 13 LTD\"), the sole general partner of NEA Partners 13, and the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors (collectively, the \"Directors\"), together, the \"Indirect Reporting Persons\"). The Directors of NEA 13 LTD are Forest Baskett, Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":3000275,"source":{"system":"sec-edgar","filing":"0001209191-24-002498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1460751/000120919124002498/doc4.xml","form_type":"4"}},{"id":1665100,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":81975,"kind":"organization","name":"NEW ENTERPRISE ASSOCIATES 13 LP","position":1,"cik":"0001452907","reported_name":"NEW ENTERPRISE ASSOCIATES 13 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock","published_at":"2024-01-31T16:55:40.000Z","date":"2024-01-29","kind":"other","planned":false,"acquired":false,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 13, L.P. (\"NEA 13\") made a pro rata distribution of 850,000 shares of Series A Common Stock of the Issuer to its general partner and limited partners for no consideration on January 29, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by NEA 13 and are indirectly held by NEA Partners 13, L.P. (\"NEA Partners 13\"), the sole general partner of NEA 13, NEA 13 GP, LTD (\"NEA 13 LTD\"), the sole general partner of NEA Partners 13, and the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the \"Directors\"), together, the \"Indirect Reporting Persons\"). The Directors of NEA 13 LTD are Forest Baskett, Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":3000275,"source":{"system":"sec-edgar","filing":"0001209191-24-002497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452907/000120919124002497/doc4.xml","form_type":"4"}},{"id":1717854,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2023-12-08T21:05:24.000Z","date":"2023-12-07","kind":"purchase","planned":false,"acquired":true,"shares":1600,"price":4.1,"value":6560.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.02 per share to $4.16 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price."}],"balance_after":627100,"source":{"system":"sec-edgar","filing":"0001104659-23-124678","document":"tm2332520-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923124678/tm2332520-1_4seq1.xml","form_type":"4"}},{"id":1732347,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29127,"kind":"person","name":"Rozek Elizabeth","position":1,"cik":"0001975022","reported_name":"Rozek Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Series A Common Stock","published_at":"2023-11-21T21:25:50.000Z","date":"2023-11-17","kind":"grant","planned":false,"acquired":true,"shares":171420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":171420,"source":{"system":"sec-edgar","filing":"0001104659-23-120377","document":"tm2331048-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923120377/tm2331048-4_4seq1.xml","form_type":"4"}},{"id":1732349,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Common Stock","published_at":"2023-11-21T21:22:35.000Z","date":"2023-11-17","kind":"grant","planned":false,"acquired":true,"shares":150750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":156380,"source":{"system":"sec-edgar","filing":"0001104659-23-120374","document":"tm2331048-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923120374/tm2331048-2_4seq1.xml","form_type":"4"}},{"id":1732600,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2023-11-21T21:21:59.000Z","date":"2023-11-17","kind":"grant","planned":false,"acquired":true,"shares":624910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":625500,"source":{"system":"sec-edgar","filing":"0001104659-23-120372","document":"tm2331048-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923120372/tm2331048-1_4seq1.xml","form_type":"4"}},{"id":1732670,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":65417,"kind":"person","name":"Martins Eduardo Bruno","position":1,"cik":"0001670431","reported_name":"Martins Eduardo Bruno","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Common Stock","published_at":"2023-11-21T16:23:31.000Z","date":"2023-11-17","kind":"grant","planned":false,"acquired":true,"shares":89570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":89570,"source":{"system":"sec-edgar","filing":"0001104659-23-120375","document":"tm2331048-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670431/000110465923120375/tm2331048-3_4seq1.xml","form_type":"4"}},{"id":1734463,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2023-11-21T02:59:29.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":590,"price":2.35,"value":1386.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.31 per share to $2.40 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each price."}],"balance_after":590,"source":{"system":"sec-edgar","filing":"0001104659-23-120027","document":"tm2331267-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923120027/tm2331267-1_4seq1.xml","form_type":"4"}},{"id":1784508,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-08T20:15:41.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":5630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":0.79,"expiration_date":"2023-09-26","underlying":"Series A Common Stock","underlying_shares":5630},"source":{"system":"sec-edgar","filing":"0001104659-23-099310","document":"tm2325723-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923099310/tm2325723-1_4seq1.xml","form_type":"4"}},{"id":1784507,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":22811,"kind":"person","name":"Kemble George","position":1,"cik":"0001858176","reported_name":"Kemble George","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Common Stock","published_at":"2023-09-08T20:15:41.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":5630,"price":0.79,"value":4447.7,"ownership":{"direct":true},"balance_after":5630,"source":{"system":"sec-edgar","filing":"0001104659-23-099310","document":"tm2325723-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923099310/tm2325723-1_4seq1.xml","form_type":"4"}},{"id":1825632,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":23216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option are fully vested and exercisable as of the date hereof."}],"balance_after":23216,"derivative":{"exercise_price":6.36,"expiration_date":"2029-04-28","underlying":"Series A Common Stock","underlying_shares":23216},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825631,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2029-04-28","underlying":"Common Stock","underlying_shares":23216},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}},{"id":1825630,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series F Preferred Stock","published_at":"2023-07-20T20:20:03.000Z","date":"2023-07-18","kind":"exercise","planned":false,"acquired":false,"shares":20430107,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC (\"KPCB PBD\"). The managing member of KPCB PBD is KPCB PBD Associates, LLC (\"KPCB PBD Associates\"). All securities are held for convenience in the name of \"KPCB Holdings, Inc., as nominee\". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Series A Common Stock","underlying_shares":257052},"source":{"system":"sec-edgar","filing":"0001104659-23-082736","document":"tm2321276-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465923082736/tm2321276-23_4seq1.xml","form_type":"4"}}],"next_cursor":"2023-07-20T20:20:03.000000Z,1825630"}